





UddfcUWzA YEfc[ fUa a YEa cghEYUWYXZhgAj YFU YE  
 [cUAf]b[ AYfghfYUa Ybhci bXh' 1 LAbXKXgE  
 ]bAh YEgWbXh\*1 E'AbAh YEi Uhm mEfYUa YbhE  
 UddfcUWzA YE+AE][ \ df]cf]hAa a i b]hYgAf[ YhXE  
 Xi f]b[ AYfghEhXgYbXhEi UhmfgEzS&&A YhA YE  
 [cUAfEW]j ]b[ A)1 AbXh\*1 Aj YU YzEgYm]j YmE  
 Si f]b[ AYgWbXhEzEzS&&ASAX]hcbUAfchUzEhE  
 \][ \ df]cf]hAa a i b]hYgE YfYh[ YhXZcfEi Uhm mE  
 hYUa YbhZcj YFU YEgYgE WgZ zEW]j ]b[ A)1 A  
 UbXE, 1 Aj YU YAbA YhA ]fXAbXhEi fhEi UhmgE  
 respectively.

bU hfgEi ]Aj UYbhEfbfUWfAYE S&Aci fbYgAZUWgKYhU  
 hA YbhBUBgEYAWYhE AfUjA YbhYa Ygf]YzEAM j Yh fYE  
 VWYEAfYgei YhfEh]bh h UAgY h h

**Serological assessments in the Yanomami Focus Area from 2018 to 2022**

Gfc`c[ ]WAEgYga Yb]gEYAWX WXXE ]hA YE@G5AE  
 Cj %AU]bcg]hWg'

**Venezuela South Focus**

-bS&&hY]a ]b]fmeYg hgZca Efc`c[ ]WAEg]b[ EZE  
 &&AW] XfYbA] YXh - AUfg]bA EZE% Aa a i b]hYg]bE  
 ' Ag VUFYgEYUfA YbU] ]UbAcfXfAg ckYXh UhE`AE  
 hcgyAghXhE YfYg]cbY] Uj YhTable 1). The results  
 cZfEgYga Yb]g]bA) Aa a i b]hYg]bEh YfAg VUFYgE  
 ]bS&AE ]`AYAdfYg]bX]b]bEj Ya VfS&AEhA YE  
 -hmf5a Y]WbAEcbZfYbWAcAbWcWVU]g]hE57CLE  
 a Yh]b]bAei UhA UU'

**Brazil Amazonas Focus**

Gfc`c[ ]WAEgYga Yb]gEYAWX WXXE]bS%ì S&&E  
 ]bS&AW] XfYbA] YXh - AUfg]bA EZEYhE]g VUFYgE  
 ]bAYZWgTable 2). Preliminary results showed an

**1 Preliminary results of Ov16 serological assessments in children aged 1–9 years in 3 subareas of the Venezuela South Focus (May–July 2022)**

**1 Résultats préliminaires des évaluations sérologiques Ov16 chez les enfants âgés de 1-9 ans dans 3 sous-zones du foyer sud du Venezuela (mai-juillet 2022)**

Subarea or sector – Sous-zone ou secteur	No. of children aged 1–5 years assessed – Nbre d'enfants âgés de 1-5 ans testés	No. of positive samples in children aged 1–5 years – Nbre d'échantillons positifs chez les enfants âgés de 1-5 ans	Prevalence in children aged 1–5 years (%) – Prévalence chez les enfants âgés de 1-5 ans (%)	No. of children aged 6–9 years assessed – Nbre d'enfants âgés de 6-9 ans testés	No. of positive samples in children aged 6–9 years – Nbre d'échantillons positifs chez les enfants âgés de 6-9 ans	Prevalence in children aged 6–9 years (%) – Prévalence chez les enfants âgés de 6-9 ans (%)	Total no. of children assessed – Nbre total d'enfants testés	Total no. of positive samples – Nbre total d'échantillons positifs	Total prevalence (%) – Prévalence totale (%)	No. of treatment rounds with 85% coverage – Nbre de tournées de traitement avec une couverture 85%
At. Cal-a / Ka. qáa ٢٠٠	18	0	0.0	22	0	0.0	40	0	0.0	10
At. Cal-a / ٨ ٤ ٢٠٠	35	0	0.0	25	0	0.0	60	0	0.0	14
٨ ٢٠٠ / Cal ١ ٢٠٠	38	0	0.0	20	0	0.0	58	0	0.0	6
٨ ٢٠٠ / At ٨ ٢٠٠	19	0	0.0	11	0	0.0	30	0	0.0	11
Ua ad / Ua ad	20	0	0.0	4	0	0.0	24	0	0.0	14
<b>Total no. of samples processed – Nbre total d'échantillons analysés</b>	<b>130</b>	<b>0</b>	<b>0.0</b>	<b>82</b>	<b>0</b>	<b>0.0</b>	<b>212</b>	<b>0</b>	<b>0.0</b>	

2 Preliminary results of Ov16 serological assessment of children aged 1–9 years in 19 subareas of the Brazil Amazonas Focus, 2018–2022

5.2 Résultats préliminaires des évaluations sérologiques Ov16 chez les enfants âgés de 1-9 ans dans 19 sous-zones du foyer de l'Amazonas au Brésil, 2018-2022

Subarea or sector – Sous-zone ou secteur	No. of children aged 1–5 years assessed – Nbre d'enfants âgés de 1-5 ans testés	No. of positive samples in children aged 1–5 years – Nbre d'échantillons positifs chez les enfants âgés de 1-5 ans	Prevalence in children aged 1–5 years (%) – Prévalence chez les enfants âgés de 1-5 ans (%)	No. of children aged 6–9 years assessed – Nbre d'enfants âgés de 6-9 ans testés	No. of positive samples in children aged 6–9 years – Nbre d'échantillons positifs chez les enfants âgés de 6-9 ans	Prevalence in children aged 6–9 years (%) – Prévalence chez les enfants âgés de 6-9 ans (%)	Total no. of children assessed – Nbre total d'enfants testés	Total no. of positive samples – Nbre total d'échantillons positifs	Total prevalence (%) – Prévalence totale (%)	No. of treatment rounds with 85% coverage – Nbre de tournées de traitement avec une couverture 85%
Alta...	424	7	1.7	285	19	6.7	709	26	3.7	21
S...	349	5	1.4	282	13	4.6	631	18	2.9	19
Xe...	203	2	1.0	162	8	4.9	365	10	2.7	36
H...	24	0	0.0	18	1	5.6	42	1	2.4	31
A.d...	85	2	2.4	53	1	1.9	138	3	2.2	28
Ha...	82	0	0.0	61	3	4.9	143	3	2.1	36
Ba.a...	73	0	0.0	44	1	2.3	117	1	0.9	43
Ha...	161	2	1.2	109	0	0.0	270	2	0.7	37
T t t b...	58	0	0.0	15	0	0.0	73	0	0.0	48
At. Pa...	32	0	0.0	18	0	0.0	50	0	0.0	21
At. Ca...	13	0	0.0	5	0	0.0	18	0	0.0	38
Ka a...	8	0	0.0	5	0	0.0	13	0	0.0	25
N B...	83	0	0.0	28	0	0.0	111	0	0.0	38
Wa...	37	0	0.0	23	0	0.0	60	0	0.0	29
Pa...	23	0	0.0	24	0	0.0	47	0	0.0	38
Pa.a...	2	0	0.0	3	0	0.0	5	0	0.0	40
Ma...ca Pa...	18	0	0.0	15	0	0.0	33	0	0.0	35
Wa...	31	0	0.0	17	0	0.0	48	0	0.0	33
Sa-ba	18	0	0.0	11	0	0.0	29	0	0.0	25
<b>Total no. of samples processed – Nbre total d'échantillons analysés</b>	<b>1724</b>	<b>18</b>	<b>1.0</b>	<b>1178</b>	<b>46</b>	<b>3.9</b>	<b>2902</b>	<b>64</b>	<b>2.2</b>	

Table 2. Preliminary results of Ov16 serological assessment of children aged 1–9 years in 19 subareas of the Brazil Amazonas Focus, 2018–2022. The table shows the number of children assessed, the number of positive samples, the prevalence percentage, the total number of children assessed, the total number of positive samples, the total prevalence percentage, and the number of treatment rounds with 85% coverage for each subarea.

Editorial note

The elimination of onchocerciasis is a major public health goal in the Amazon region of Brazil. This assessment is a key step in the process of onchocerciasis elimination, included intercommunity...

